RxDoctor Payments Data

Gregorius Penilla, MD

Internal Medicine · Fenton, MONPI 1023024973

Payments from drug & device makers

$8,240in general payments, 2019–2025

Across 34 payments — averaging $242.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
  • AstraZeneca$1K
  • Amgen$469
  • Amarin Pharma, Inc.$319
  • Bayer$115
  • Exact Sciences$35
  • plus $11 from 1 others

What the payments were for

  • Consulting fees$4,16150%
  • Travel & lodging$1,86223%
  • Food & beverage$2,20527%
  • Education$120%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,240 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$91,723
Medicare patients
196
Services billed
1,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin71$105,651
FarxigaDapagliflozin Propanediol70$94,499
EliquisApixaban53$79,016
TrulicityDulaglutide31$45,428
ArexvyRsvpref3 Antigen/As01e/Pf122$29,716
JanuviaSitagliptin Phosphate13$20,626
VascepaIcosapent Ethyl23$20,589
RybelsusSemaglutide11$20,198
OzempicSemaglutide13$19,716
Spiriva HandihalerTiotropium Bromide17$8,515
Breo ElliptaFluticasone/Vilanterol12$8,459
Atorvastatin Calcium830$5,327
SynthroidLevothyroxine Sodium40$4,037
SymbicortBudesonide/Formoterol Fumarate17$3,892
AbrysvoRsv Vacc, Pref A And Pref B/Pf17$3,799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$1,056$98,39187 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Fenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →